Study on the Efficacy and Safety of Vericiguat in Patients with Acute Myocardial Infarction Combined with Mildly Reduced Ejection Fraction (LVEF: 45–50%)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600119767

Enrollment

Unknown

Registered

2026-03-03

Start date

2026-03-05

Completion date

Unknown

Last updated

2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

Group A (Experimental Group):On the basis of guideline-directed standard treatment (ACEI/ARB/ARNI, ß-blockers, diuretics, SGLT2i, etc.), oral vericiguat 5 mg is administered once daily. Treatment shou

according to the subject’s tolerance, the dose can be adjusted to 10 mg once daily after 2 weeks.

Group B (Control Group):Receive guideline-standard treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >=18 years; 2. Diagnosed with acute myocardial infarction within the past 30 days; 3. LVEF between 45%-50%; 4. NT-proBNP >=300 pg/mL or BNP >=100 pg/mL.

Exclusion criteria

Exclusion criteria: 1. Systolic blood pressure 3×ULN, etc.); 5. Other severe diseases (severe infection, malignant tumors, expected survival <1 year, etc.); 6. Other myocardial diseases

Design outcomes

Primary

Measure	Time frame
NT-proBNP/BNP;Absolute improvement in left ventricular ejection fraction (LVEF) compared to baseline (%);Incidence of major adverse events (hypotension, syncope, renal function deterioration, etc.);	—

Secondary

Measure	Time frame
Size of the heart chambers ;Interventricular septal thickness;KCCQ-12 Quality of Life Score Changes;	—

Countries

China

Contacts

Public ContactYushi Wang

The First Hospital of Jilin University

yushi@jlu.edu.cn+86 135 9605 3499

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026